Search research articles
Contact Us
Filters
Showing results (271-280 of 306) with videos related to
Page
of 31
Sort By:
Liver Cancer
|
February 20, 2020
<sup>18</sup>F-Fluorodeoxyglucose Uptake in Hepatocellular Carcinoma as a Useful Predictor of an Extremely Rapid Response to Lenvatinib
Yusuke Kawamura, Masahiro Kobayashi, Junichi Shindoh, et al.
Clinical Journal of Gastroenterology
|
November 7, 2022
Well-preserved liver function enhances the clinical impact of curative-intent subsequent treatment during lenvatinib treatment for unresectable hepatocellular carcinoma
Yusuke Kawamura, Norio Akuta, Junichi Shindoh, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
January 13, 2012
Prevalence and predictive factors of diabetes in hepatitis virus positive liver cirrhosis with fasting plasma glucose level of <126 mg/dL
Naoki Matsumoto, Yasuji Arase, Yuya Seko, et al.
Liver Cancer
|
July 11, 2020
Pretreatment Heterogeneous Enhancement Pattern of Hepatocellular Carcinoma May Be a Useful New Predictor of Early Response to Lenvatinib and Overall Prognosis
Yusuke Kawamura, Masahiro Kobayashi, Junichi Shindoh, et al.
JHEP Reports : Innovation in Hepatology
|
December 13, 2023
HBcrAg-based risk score performs better than the HBV DNA-based scores for HCC prediction in grey zone patients who are HBeAg-negative
Tai-Chung Tseng, Tetsuya Hosaka, Chun-Jen Liu, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
January 17, 2015
Factors associated with the effect of interferon-α sequential therapy in order to discontinue nucleoside/nucleotide analog treatment in patients with chronic hepatitis B
Akihiro Matsumoto, Hiroshi Yatsuhashi, Shinya Nagaoka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
September 26, 2024
Newly established borderline resectable 1 (BR1) category is one of the favorable candidates for selecting the use of multidisciplinary combination therapy in patients with advanced hepatocellular carcinoma treated with systemic therapy
Yusuke Kawamura, Norio Akuta, Junichi Shindoh, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
May 3, 2025
Peripheral blood CD4+/CD8+ T cell ratio may have potential for predicting the treatment response of durvalumab plus tremelimumab therapy (STRIDE) for unresectable hepatocellular carcinoma: Preliminary report
Yusuke Kawamura, Norio Akuta, Junichi Shindoh, et al.
Internal Medicine (Tokyo, Japan)
|
June 26, 2020
Diagnosis and Resection Treatment of Triplet Hepatocellular Carcinomas with a non-B non-C Background in a Middle Aged Man over a Period of 6-years
Akira Kajiwara, Keiichi Kinowaki, Norio Akuta, et al.
Internal Medicine (Tokyo, Japan)
|
May 8, 2024
Long-term Favorable Efficacy of Regular and Repeated Hospitalizations with a Personalized Diet and Exercise Treatment for Steatotic Liver Disease
Norio Akuta, Yusuke Kawamura, Hitomi Sezaki, et al.
Page
of 31
Search research articles
Search
Showing results (271-280 of 306) with videos related to
Sort By:
Page
of 31
Liver Cancer
|
February 20, 2020
<sup>18</sup>F-Fluorodeoxyglucose Uptake in Hepatocellular Carcinoma as a Useful Predictor of an Extremely Rapid Response to Lenvatinib
Yusuke Kawamura, Masahiro Kobayashi, Junichi Shindoh, et al.
Clinical Journal of Gastroenterology
|
November 7, 2022
Well-preserved liver function enhances the clinical impact of curative-intent subsequent treatment during lenvatinib treatment for unresectable hepatocellular carcinoma
Yusuke Kawamura, Norio Akuta, Junichi Shindoh, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
January 13, 2012
Prevalence and predictive factors of diabetes in hepatitis virus positive liver cirrhosis with fasting plasma glucose level of <126 mg/dL
Naoki Matsumoto, Yasuji Arase, Yuya Seko, et al.
Liver Cancer
|
July 11, 2020
Pretreatment Heterogeneous Enhancement Pattern of Hepatocellular Carcinoma May Be a Useful New Predictor of Early Response to Lenvatinib and Overall Prognosis
Yusuke Kawamura, Masahiro Kobayashi, Junichi Shindoh, et al.
JHEP Reports : Innovation in Hepatology
|
December 13, 2023
HBcrAg-based risk score performs better than the HBV DNA-based scores for HCC prediction in grey zone patients who are HBeAg-negative
Tai-Chung Tseng, Tetsuya Hosaka, Chun-Jen Liu, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
January 17, 2015
Factors associated with the effect of interferon-α sequential therapy in order to discontinue nucleoside/nucleotide analog treatment in patients with chronic hepatitis B
Akihiro Matsumoto, Hiroshi Yatsuhashi, Shinya Nagaoka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
September 26, 2024
Newly established borderline resectable 1 (BR1) category is one of the favorable candidates for selecting the use of multidisciplinary combination therapy in patients with advanced hepatocellular carcinoma treated with systemic therapy
Yusuke Kawamura, Norio Akuta, Junichi Shindoh, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
May 3, 2025
Peripheral blood CD4+/CD8+ T cell ratio may have potential for predicting the treatment response of durvalumab plus tremelimumab therapy (STRIDE) for unresectable hepatocellular carcinoma: Preliminary report
Yusuke Kawamura, Norio Akuta, Junichi Shindoh, et al.
Internal Medicine (Tokyo, Japan)
|
June 26, 2020
Diagnosis and Resection Treatment of Triplet Hepatocellular Carcinomas with a non-B non-C Background in a Middle Aged Man over a Period of 6-years
Akira Kajiwara, Keiichi Kinowaki, Norio Akuta, et al.
Internal Medicine (Tokyo, Japan)
|
May 8, 2024
Long-term Favorable Efficacy of Regular and Repeated Hospitalizations with a Personalized Diet and Exercise Treatment for Steatotic Liver Disease
Norio Akuta, Yusuke Kawamura, Hitomi Sezaki, et al.
Page
of 31